OpenAI researcher Miles Wang is leaving to launch an AI drug discovery startup and is in talks to raise $200M at a $2B valuation, with Lightspeed potentially leading the round. The new venture, which may focus on repurposing existing drugs, enters a hot market where competitors like Chai Discovery and Isomorphic Labs have recently raised billions. Wang has disputed the reported funding figures.
Aug 8, 2026 · 2 sources
Aug 7, 2026 · 2 sources
Aug 7, 2026 · 8 sources
Aug 7, 2026 · 1 source
Story comments
Loading comments…